Related Experiment Video
Updated: May 17, 2026
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Possible relationship between Al/ferritin complex and Alzheimer's disease
Pasquale De Sole1, Cristina Rossi, Michela Chiarpotto
1Laboratory of Clinical Biochemistry - Policlinico Agostino Gemelli, Catholic University, Rome, Italy. p.desole@rm.unicatt.it
Clinical Biochemistry
|October 30, 2012
Summary
Alzheimer's disease patients show higher aluminum levels in ferritin, a key iron-storage protein. This finding supports aluminum's role in Alzheimer's and suggests potential new diagnostic approaches for the neurodegenerative condition.
Area of Science:
- Neurochemistry
- Biochemistry
- Toxicology
Background:
- Ferritin is the primary iron-storage protein, capable of binding thousands of iron atoms.
- In vivo studies show ferritin can also store other metals like aluminum and zinc.
- Aluminum's potential involvement in Alzheimer's disease pathogenesis necessitates further investigation.
Purpose of the Study:
- To quantify and compare the aluminum content in ferritin between Alzheimer's disease patients and control groups.
- To explore the functional role of ferritin in regulating toxic metal accumulation.
- To investigate the relationship between ferritin-bound aluminum and Alzheimer's disease progression.
Main Methods:
- Blood ferritin samples were collected from Alzheimer's disease patients and various control groups.
- Mass spectrometry was employed to measure the concentrations of iron (Fe), aluminum (Al), and zinc (Zn) in ferritin.
- Statistical analysis compared metal content across different patient and control cohorts.
Main Results:
- Ferritin from Alzheimer's disease patients exhibited significantly higher aluminum content compared to control groups.
- The study confirmed ferritin's role as a regulatory protein for toxic metals.
- Elevated aluminum levels in ferritin were observed in Alzheimer's patients.
Conclusions:
- The specific aluminum content within ferritin appears correlated with different stages of Alzheimer's disease.
- These findings support the hypothesis that aluminum may be a contributing factor in Alzheimer's disease development.
- The results open avenues for developing novel diagnostic tools for Alzheimer's disease based on ferritin-bound aluminum levels.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...